Research map: Hematological neoplasms after PRRT: experience from long term follow-up of 173 patients in a tertiary center

Back to the article

Papers in this map

  1. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors · Tessa Brabander · 2017 · 619 citations · Cited by this paper
  2. HbA1c screening in patients with early breast cancer receiving endocrine therapy · 2025 · Related
  3. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial · Jonathan R Strosberg · 2021 · 583 citations · Cited by this paper
  4. Survival and prognostic differences between appendiceal NETs and goblet cell adenocarcinomas · 2025 · Related
  5. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors · Lisa Bodei · 2014 · 473 citations · Cited by this paper
  6. Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE · 2025 · Related
  7. Risk of Leukemia after Chemotherapy and Radiation Treatment for Breast Cancer · Rochelle E. Curtis · 1992 · 454 citations · Cited by this paper
  8. 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence · 2025 · Related
  9. Therapy-related myeloid neoplasms: when genetics and environment collide · Megan E. McNerney · 2017 · 426 citations · Cited by this paper
  10. Cytologically non-malignant thyroid nodules with three or more high-risk genetic mutations have poor outcomes · 2025 · Related
  11. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study · Simron Singh · 2024 · 374 citations · Cited by this paper
  12. To screen or not to screen: complexity of SDHA mutation management · 2026 · Related
  13. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity · Ulrike Garske‐Román · 2018 · 260 citations · Cited by this paper
  14. Adrenal crisis due to pembrolizumab-induced hypophysitis in a patient with triple-negative breast cancer · 2025 · Related
  15. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma · Grace Kong · 2017 · 170 citations · Cited by this paper
  16. Using routinely collected patient data to study the impact of type 2 diabetes on breast cancer · 2025 · Related
  17. Long-Term Hematotoxicity After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate · Amir Sabet · 2013 · 169 citations · Cited by this paper
  18. Patient-reported symptom and urgent healthcare use in neuroendocrine tumors · 2026 · Related
  19. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours · Wouter A. van der Zwan · 2018 · 146 citations · Cited by this paper
  20. Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms · Richard Paul Baum · 2018 · 142 citations · Cited by this paper
  21. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors · Hendrik Bergsma · 2017 · 140 citations · Cited by this paper
  22. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series · Isaac Goncalves · 2019 · 67 citations · Cited by this paper
  23. High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy · Bertrand Brieau · 2016 · 65 citations · Cited by this paper
  24. Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors · Silvia Nicolini · 2021 · 64 citations · Cited by this paper
  25. Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy · Mohamad Bassam Sonbol · 2020 · 63 citations · Cited by this paper
  26. 177Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants · Katarzyna Fröss‐Baron · 2020 · 47 citations · Cited by this paper
  27. Therapy-related myeloid neoplasm after peptide receptor radionuclide therapy (PRRT) in 1631 patients from our 20 years of experiences: prognostic parameters and overall survival · Maythinee Chantadisai · 2020 · 43 citations · Cited by this paper
  28. Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177 Lu‐octreotate peptide radionuclide therapy · Kim Robyn Kennedy · 2022 · 32 citations · Cited by this paper
  29. Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) and capecitabine plus temozolomide (CAPTEM) for pancreas and midgut neuroendocrine tumours (pNETS, mNETS)—Final results. · Nick Pavlakis · 2022 · 32 citations · Cited by this paper
  30. Semiautomatic Tumor Delineation for Evaluation of 64 Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume · Esben Andreas Carlsen · 2021 · 31 citations · Cited by this paper
  31. Therapy-Related Myeloid Neoplasms: Complex Interactions among Cytotoxic Therapies, Genetic Factors, and Aberrant Microenvironment · Deepak Singhal · 2024 · 29 citations · Cited by this paper
  32. Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors · Yuanyuan Jiang · 2022 · 28 citations · Cited by this paper
  33. Treatment of myelodysplastic syndrome in the era of next‐generation sequencing · Magnus Tobiasson · 2019 · 25 citations · Cited by this paper
  34. Update in the management of gastroenteropancreatic neuroendocrine tumors · Andrew J. H. Sedlack · 2024 · 25 citations · Cited by this paper
  35. Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden · Denise A. Gococo-Benore · 2023 · 14 citations · Cited by this paper
  36. [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial · Thomas Walter · 2026 · 9 citations · Cited by this paper

Source: OpenAlex (CC0)